Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS ; Offers Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $38.8 million versus the consensus estimate of $38.12 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $145-155 million, versus the consensus of $152.6 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Venezuela oil export revenue rises 21.5% in first quarter
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future